Literature DB >> 20722029

Risk factors for severe Muckle-Wells syndrome.

Jasmin B Kümmerle-Deschner1, Pascal N Tyrrell, Fabian Reess, Ina Kötter, Peter Lohse, Hermann Girschick, Christian Huemer, Gerd Horneff, Johannes-Peter Haas, Assen Koitschev, Christoph Deuter, Susanne M Benseler.   

Abstract

OBJECTIVE: Muckle-Wells syndrome (MWS) is an inherited autoinflammatory disease resulting in excessive interleukin-1 release. It is unknown whether demographic, clinical, or laboratory characteristics at the time of diagnosis may identify patients who are at high risk for severe disease activity. This study was undertaken to analyze clinical and laboratory features of MWS, compare genetically defined subcohorts, and identify risk factors for severe MWS.
METHODS: A multicenter cohort study of consecutive MWS patients was performed. Parameters assessed included clinical features, MWS Disease Activity Score (MWS-DAS), inflammation markers, and cytokine levels. E311K mutation-positive patients were compared with E311K mutation-negative patients. Putative risk factors for severe MWS (defined as an MWS-DAS score of ≥10) were assessed in univariate analyses, and significant predictors were entered into a multivariate model.
RESULTS: Thirty-two patients (15 male and 17 female) were studied. The most frequent organ manifestations were musculoskeletal symptoms and eye and skin disorders. Renal disease and hearing loss were seen in >50% of the patients. Genetically defined subcohorts had distinct phenotypes. Severe disease activity was documented in 19 patients (59%). Predictors of severe MWS identified at the time of diagnosis were female sex, hearing loss, musculoskeletal disease, increased erythrocyte sedimentation rate, and low hemoglobin level. Female sex and hearing loss remained significant after adjustment for age in a multivariate model (relative risk 1.8 and 2.6, respectively).
CONCLUSION: MWS patients at high risk for severe disease can be identified at the time of diagnosis. Female patients presenting with hearing loss have the highest likelihood of manifesting severe MWS and should be considered a high-risk group.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722029     DOI: 10.1002/art.27696

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

1.  "Mutation negative" familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies.

Authors:  C M Hedrich; N Bruck; D Paul; G Hahn; M Gahr; A Rösen-Wolff
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

Review 2.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 3.  Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi
Journal:  World J Nephrol       Date:  2016-01-06

4.  [Cryopyrin-associated periodic syndrome].

Authors:  J B Kümmerle-Deschner
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

5.  Muckle-Wells syndrome in Chinese patients: a single center case series.

Authors:  Di Wu; Min Shen
Journal:  Clin Rheumatol       Date:  2016-12-27       Impact factor: 2.980

6.  The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

Authors:  Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya
Journal:  Arthritis Rheumatol       Date:  2022-05-27       Impact factor: 15.483

Review 7.  Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.

Authors:  Jasmin B Kuemmerle-Deschner; Iris Haug
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

8.  Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab.

Authors:  Roberto Scarpioni; Donato Rigante; Luca Cantarini; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa; Antonio Lazzaro
Journal:  Clin Rheumatol       Date:  2014-02-09       Impact factor: 2.980

9.  Hereditary autoinflammatory syndromes: a Brazilian multicenter study.

Authors:  Adriana A Jesus; Erika Fujihira; Mariana Watase; Maria T Terreri; Maria O Hilario; Magda Carneiro-Sampaio; Claudio A Len; Sheila K Oliveira; Marta C Rodrigues; Rosa M Pereira; Blanca Bica; Nilzio A Silva; Andre Cavalcanti; Roberto Marini; Flavio Sztajnbok; Maria V Quintero; Virginia P Ferriani; Dewton Moraes-Vasconcelos; Clovis A Silva; Joao B Oliveira
Journal:  J Clin Immunol       Date:  2012-05-08       Impact factor: 8.317

10.  NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment.

Authors:  Jasmin B Kuemmerle-Deschner; Peter Lohse; Ina Koetter; Guenther E Dannecker; Fabian Reess; Katharina Ummenhofer; Silvia Koch; Nikolay Tzaribachev; Anja Bialkowski; Susanne M Benseler
Journal:  Arthritis Res Ther       Date:  2011-12-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.